Compelling evidence suggests that PCK1 is strongly expressed in CRC cells and that PCK1 promotes cancer cell proliferation by increasing the anabolic utilization of glucose and glutamine.
The expression of PCK1 in cancer is tissue-specific.
PCK1’s expression and role in cancer are complex and vary by tissue type and tumor microenvironment. In cancers such as hepatocellular carcinoma, PCK1 is often downregulated and this reduction is associated with poorer prognosis and a more aggressive tumor phenotype, suggesting a tumor-suppressive role. In other cancers such as colorectal, lung, or breast cancer, findings are mixed and depend on the metabolic context, with some evidence pointing to altered PCK1 levels contributing to metabolic reprogramming that supports tumor growth.
(Will delete Record if Target field = "Delete") Home